21.4 C
New York
Thursday, June 4, 2026

Tag: disability

newssourceFORcompanyinformationcontent1marketreleases

Great-West Lifeco reports record base earnings and announces intention for additional $500 million in share buybacks

TSX:GWO Great-West Lifeco Inc.'s Quarterly Report to Shareholders for the second quarter of 2025, including its Management's Discussion and Analysis (MD&A) and consolidated financial statements...

PropsNoMore.org Launches to Promote Authentic Disability Representation

Not Your Tragedy, Not Your Inspiration  SAN DIEGO, Aug. 5, 2025 /PRNewswire/ -- The Global Alliance for Disability in Media and Entertainment (GADIM) is proud...

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in...

This Isn’t Rare. It’s Just Overlooked. Let’s Do Better for Kids with Prenatal Substance Exposure

By Mary Kirchoff, CEO of Wonderland Child & Family Services / Hope Rising Clinic BOTHELL, Wash., July 30, 2025 /PRNewswire/ -- A recent article highlighted...

New Affordable Housing Development to Deliver 110 Units to Oceanside’s Mira Costa Neighborhood

WNC & Associates, MirKa Investments, LLC, and Mission Neighborhood Centers, Inc. begin construction on El Camino Real 
WNC & Associates, MirKa Investments, LLC, and Mission Neighborhood Centers, Inc. begin construction on El Camino Real

PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on...

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November 
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

Wellcome Photography Prize 2025: Winning Images Reveal Powerful Stories of Science and Health

Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol 
Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

VLN Commercial Launches Confirm Viability of the FDA’s Proposed Reduced Nicotine Mandate

Multiple Tobacco Brands Partnering with 22nd Century to Expand Availability and Awareness of VLN Based Reduced Nicotine Content Products 

Chronic Conditions Surge in U.S. Workforce While Disability Claims Decline, Signaling a New Workforce Health Paradox

OAKLAND, Calif., June 26, 2025 /PRNewswire/ -- More than 78% percent of employees in the US now have at least one chronic condition, an...

Access Ready Strategic Joins Families USA and the CCD Rights Task Force Along with Other Organizations on Vital Policy and Public Interest Positions

Many Groups and Organizations respond on Policy Issues WASHINGTON, June 26, 2025 /PRNewswire/ -- The recent rapid approach to policy changes at the Federal and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDisability

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers